Berlin is set to host bio:cap, an innovative investival focusing on the convergence of life sciences and artificial intelligence, from June 9-11, 2026. This inaugural event will gather a diverse mix of stakeholders, including investors, startups, and research institutions, at the CityCube venue.
Europe's robust life sciences ecosystem, characterized by leading universities and research institutes, positions it as a frontrunner in biotechnology advancements. bio:cap aims to harness this potential by fostering connections among research, investment, and industry, thereby accelerating the journey from scientific discovery to viable medical solutions.
The event will cover the entire innovation spectrum, addressing key themes such as Europe's role in global biotechnology, the impact of AI on research and drug development, and new therapeutic avenues beyond mRNA. Notable speakers include Nobel laureate Prof. Dr. Stefan W. Hell and industry leaders from Bayer and CRISPR Therapeutics, emphasizing the collaborative spirit necessary for advancing life-science innovation.
Organized by Messe Berlin in partnership with prominent institutions like Charité and the Berlin Institute of Health, bio:cap will feature curated matchmaking sessions to enhance collaboration within the international life sciences community. As Berlin emerges as a vibrant hub for life sciences, this event aims to solidify its status and promote the synergy between science, entrepreneurship, and capital investment.